Cross-sectional studies show that around half of individuals infected with HIV-1 have some
degree of cognitive impairment despite the use of antiretroviral drugs. However, prevalence …

HIV-positive patients may be effectively treated with highly active antiretroviral therapy and
such a strategy is associated with striking immune recovery and viral load reduction to very …

HIV infection has become a chronic illness when successfully treated with combined
antiretroviral therapy (cART). The long-term health prognosis of aging with controlled HIV …

HIV-associated neurocognitive disorders (HAND) is a group of syndromes of varying
degrees of cognitive impairment affecting up to 50% of HIV-infected individuals. The …

HIV-1-infected patients with suppressed plasma viral loads often require changes to their
antiretroviral (ARV) therapy to manage drug toxicity and intolerance, to improve adherence …

Illicit drug users are a high-risk population for infection with the human immunodeficiency
virus (HIV). A strong correlation exists between prohibited drug use and an increased rate of …

Monotherapy with boosted protease inhibitors has emerged as an antiretroviral therapy
simplification alternative for selected patients, endorsed by the results of some randomized …

Inflammation in people living with HIV (PLWH) correlates with severity of HIV-associated
neurocognitive disorders. The objective of this study is to identify blood-based markers of …

Background and Objective Significant controversy still exists about ritonavir-boosted
protease inhibitor monotherapy (mtPI/rtv) as a simplification strategy that is used up to now …

Background. To determine whether treatment with ritonavir-boosted protease inhibitor (PI)
monotherapy is associated with detrimental effects on neurocognitive function or brain …